SCHEMBL6523153

SCHEMBL6523153

CC(=O)O[C@@H](C(=O)O)[C@@H](OC(C)=O)C(=O)N(CCCl)c1ccc(C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
CYP3A4 P08684 3/20 0.36
LMNA P02545 3/20 0.36
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 2/20 0.36
HIF1A Q16665 2/20 0.36
ABCB11 O95342 1/20 0.36
CHRM2 P08172 1/20 0.36
ADRA2A P08913 1/20 0.36
CHRM1 P11229 1/20 0.36
ACHE P22303 1/20 0.36
PTGS1 P23219 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP1A2 P05177 1/20 0.36
NFKB1 P19838 1/20 0.36
THPO P40225 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949186 0.93 NPC1 (0.35) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL6527272 0.90 KMT2A (0.37) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL6519022 0.89 ALDH1A1 (0.36) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL6521242 0.89 CYP3A4 (0.36) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL6525920 0.86 MLYCD (0.34) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL6520946 0.85 POLB (0.38) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL1438225 0.85 RECQL (0.46) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL1440585 0.85 MLYCD (0.39) SMN1; SMN2CYP3A4LMNAALDH1A1ALOX15
SCHEMBL1949940 0.84 LMNA (0.35) SMN1; SMN2LMNA
SCHEMBL6526993 0.83 SERPINE1 (0.40) TDP1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373634-B1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARM CO LTD (JP) 2015-11-11 EP disclosed
US-8987242-B2 Morpholinone compounds as factor IXA inhibitors MERCK SHARP & DOHME CORP. (US) 2015-03-24 US disclosed
US-8642582-B2 Morpholinone compounds as factor IXa inhibitors MERCK SHARP & DOHME CORP. (US) 2014-02-04 US disclosed
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059958-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS SERPINC1, F9, F8 SMN1; SMN2 1538/4885CYP3A4 3914/4885LMNA 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.